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StenosisSynthetic arteriovenous (AV) hemodialysis grafts are plagued by hyperplasia resulting in occlusion and graft
failure yet there are no clinically available preventative treatments. Here the delivery and degradation of a
sirolimus-laden polymer gel were monitored in vivo by magnetic resonance imaging (MRI) and its efﬁcacy
for inhibiting hyperplasia was evaluated in a porcine model of AV graft stenosis.
Synthetic grafts were placed between the carotid artery and ipsilateral jugular vein of swine. A biodegradable
polymer gel loaded with sirolimus (2.5 mg/mL) was immediately applied perivascularly to the venous anas-
tomosis, and reapplied by ultrasound-guided injections at one, two and three weeks. Control grafts received
neither sirolimus nor polymer. The lumen cross-sectional area at the graft–vein anastomosis was assessed in
vivo by non-invasive MRI. The explanted tissues also underwent histological analysis.
A speciﬁcally developedMRI pulse sequence provided a high contrast-to-noise ratio (CNR) between the polymer
and surrounding tissue that allowed conﬁrmation of gel location after injection. Polymer signal decreased up to
80% at three to four weeks after injection, slightly faster than its degradation kinetics in vitro. The MR image of
the polymer was conﬁrmed by visual assessment at necropsy. On histological assessment, the mean hyperplasia
surface area of the treated graft was 52% lower than that of the control grafts (0.43 mm2 vs. 0.89 mm2; pb0.003),
while the minimum cross-sectional lumen area, as measured on MRI, was doubled (5.3 mm2 vs 2.5 mm2;
pb0.05).
In conclusion, customizedMRI allowed non-invasivemonitoring of the location and degradation of drug delivery
polymer gels in vivo. Perivascular application of sirolimus-laden polymer yielded a signiﬁcant decrease in hyper-
plasia development and an increase in lumen area at the venous anastomosis of AV grafts.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
A reliable vascular access providing high blood ﬂow rates is critical
for chronic hemodialysis. Access for hemodialysis is preferably achieved






In vivo evaluation of the del
l. Release (2012), doi:10.101artery to receive arterial ﬂow, or through the placement of a synthetic
graft between the artery and vein. In contrast to the native arteriovenous
(AV) ﬁstula, the synthetic AV graft quickly andmore reliably produces an
access with sufﬁciently high blood ﬂow rates necessary for hemodialysis;
however synthetic grafts suffer from a high rate of stenosis due to aggres-
sive hyperplasia development typically at the anastomosis between the
vein and graft [1]. The nativeAVﬁstulas have a lower incidence of stenosis
and clotting than synthetic AV grafts. However,ﬁstulas sometimes cannot
be created due to inadequate blood vessel size or condition, and up to 60%
of ﬁstulas fail to develop sufﬁcient blood ﬂow to achieve dialysis [2]. If the
primary patency of the synthetic AV graft could be signiﬁcantly pro-
longed, these conduits would prove an attractive alternative to the native
ﬁstula.ivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
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for AV graft stenosis. Of note, in a recent clinical study, the placement
of polytetraﬂuoroethylene-encapsulated nitinol stents after balloon
angioplasty of stenotic lesions in synthetic AV grafts was shown to be
associated with signiﬁcantly less restenosis than balloon angioplasty
alone [3]. However, the rates of subsequent thrombotic occlusion
were similar between the two groups and even with stent placement,
approximately one third of treated graftswere lost to thrombosis. Addi-
tionally, the primary patency of the vascular access after stent place-
ment was less than 40% at six months, indicating that preventive
therapies are still urgently needed to prolong AV graft patency.
Sirolimus (rapamycin) is a macrolide antibiotic that is administered
orally for preventing rejection of organ transplants and is employed in
drug-eluting coronary stents for targeted intraluminal delivery after
angioplasty to inhibit restenosis. Drug-eluting stents have the disad-
vantage in that the drug is usually exhausted within approximately
three months of application with no means of replenishment. Angio-
plasty to treat stenotic lesions is a solitary insult to the vascular wall;
therefore, the limited duration of release of anti-proliferative drugs
from a drug-eluting stent may be a reasonable strategy to prevent
restenosis. In contrast, the hemodialysis access suffers long-term fre-
quent insults as it is punctured repeatedly for thrice-weekly dialysis
sessions. The repeat needle punctures instigate platelet activation and
thrombosis with subsequent release of growth and migratory factors
such as platelet-derived growth factor and ﬁbroblast-growth factor.
In addition, the continual presence of the foreign material of the graft
itself promotes inﬂammation and vascular cell proliferation. Lastly,
the end-stage renal disease population has unique risk factors for
stenosis such as uremia and hypercoaguability [2,4]. Consequently,
the unique characteristics of the AV graft and its abnormal physiological
environment may require repeat sustained drug delivery to inhibit ste-
nosis during the lifetime of the access.
Superﬁcial hemodialysis grafts are readily accessible percutaneously.
Thus, the placement of a perivascular depot could be a straightforward
technique to provide sustained delivery of anti-proliferative drugs for
inhibition of vascular hyperplasia. We previously reported that serial
injections of a sustained delivery, biodegradable, biocompatible,
polymer gel (ReGel™) loaded with sirolimus provided high, local-
ized, concentrations of drug at target vascular tissues in a porcine
model of AV graft stenosis [5]. Here, we extend that work and report
the efﬁcacy outcome. We show that serial injections of the drug-laden
polymer inhibited hyperplasia development in the porcine model of
AV graft stenosis. We also report the use of MRI for the in vivo tracking
of the polymer gel location and gel degradation aswell as assessment of







 Fig. 1. Porcine model.2. Materials and methods
2.1. Porcine model of AV graft stenosis
Yorkshire cross-domestic pigs were used for graft implantation as
previously described by our laboratory [6] and as described in detail in
the Online Data Supplement. Brieﬂy, under sterile conditions, a 7-cm
length of expanded polytetraﬂuoroethylene (ePTFE) graft (Bard Pe-
ripheral Vascular Inc., Tempe, AZ) was placed between the common
carotid artery and the ipsilateral external jugular vein to create a graft-
end-to-vessel-side anastomoses so that arterial blood ﬂowwas shunted
into the vein (Fig. 1). Blood samples were drawn for basic blood chem-
istries (Antech Diagnostics, Salt Lake City, UT) and plasma sirolimus
levels (ARUP Laboratories, Salt Lake City, UT).
Animals were randomly assigned to receive local sirolimus treat-
ment (treated group) or no treatment to the graft (control group).
Sirolimus powder (LC Laboratories, Woburn, MA) was mixed in vitro
with a liquid polymer gel (see below), to yield a ﬁnal concentration
of 2.5 mg/mL. This concentration was chosen based on a previousPlease cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101pharmacokinetic study demonstrating that sustained tissue drug con-
centrations, above the IC50 for inhibiting smooth muscle cell prolifer-
ation, were achieved in the anastomotic tissue [5]. Additionally in the
pharmacokinetic studies, this dose was well tolerated. The polymer–
drug suspension was maintained at 4 °C until its application to the
venous anastomosis of the AV graft in the pig. No polymer or sirolimus
was applied to animals in the control group.
All animal work was performed according to protocols approved
by the Institutional Animal Care and Use Committee of the University
of Utah and Veterans Affairs Salt Lake City Healthcare System and
conformed to the guidelines established by the Guidelines for the Care
and Use of Laboratory Animals (NIH Publication No. 85-23, revised
1996).
2.2. Polymer gel
The polymer used for these studies is a thermosensitive biodegrad-
able ABA triblock copolymer, with an average molecular weight (Mav)
of approximately 4200. The A block is poly(D,L-lactide-co-glycolide)
and the B block is polyethylene glycol (PEG) (ReGel™, Protherics Salt
Lake City, Inc., a BTG Company). The polymer is prepared by a ring-
opening of D,L-lactide, glycolide and PEG initiated by addition of stan-
nous octoate and partially characterized by 1HNMR and gel permeation
chromatography [7]. This polymer exists as an aqueous liquid (sol) state
when below its gelation temperature (15 °C) and in this form can be
mixed with drug. It transitions spontaneously into a semi-solid state
above 15 °C, serving as a localized, sustained-release drug depot at the
site of application. The polymer degrades over a period of weeks, into
lactic acid, glycolic acid and PEG. We previously studied the in vivo re-
lease kinetics of sirolimus from this gel system and reported that,
using the application protocol described in Table 1, levels of sirolimusivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
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cantly greater than concentrations needed to inhibit smooth muscle
cell proliferation in vitro [5].
2.3. Ultrasound (US)-guided injection of sirolimus-laden polymer
Besides the direct intra-operative application to the venous anas-
tomosis, the drug-treated animals also received US-guided injections
of 2 mL of liquid sirolimus-laden polymer (2.5 mg/mL) at the anasto-
motic perivascular region of the vein graft (see Fig. 2) at one, two and
three weeks after graft placement (see Table 1). A sequence of US im-
ages taken before and after injection of the polymer to the perivascu-
lar area of the graft–vein anastomosis in one animal is shown in
Fig. 2. An echogenic signal occurred upon injection but shadows
were cast by the gel that prohibited visualization of the blood vessel
and other structures beneath the gel. This hindered assessment of
the spatial relationship between the graft and blood vessels and
the injected polymer. Lastly, in contrast to MR images shown below,
when the injection sites were examined by US oneweek later, very little
echogenicity was typically observed (not shown), suggesting that the
sensitivity of US in detecting polymer gels at the perivascular region is
limited. After injection, attempts weremade to locate gel by gross visual
inspection of the surgical cavity after reopening of the wound. However,
as the gel is opaque and thewound area contained sera/exudate and clot
up to twoweeks postoperatively that obscured the view, these attempts
were not successful. Polymerwas also injected into themuscle above the
graft in one animal as described in the Results section. Animals were
subjected to weekly AV graft patency monitoring using color Doppler
US.
2.4. In vivo MRI for visualization of polymer gel and AV graft
In vitroMRI experiments were performed to determine the appro-
priate parameters that were used to differentiate polymer gel from
sera in MR images (described in detail in the Online Supplement).
For in vivo MRI, sedated animals were transported to the MR scanner
(3T Trio, Siemens Medical Solutions, Erlangen, Germany) within 1 h
after injection of the polymer. The animals were placed in a supine
position within the bore of the magnet. Images were obtained using
an overlap-decoupled 16-channel phased-array radio frequency (RF)
coil mounted on a ﬁberglass support molded to ﬁt the porcine neck,
placed directly over the surgical site, or with eight total coil elements
forming two sets of bilateral pair array coils. A localization scan was
performed using axial 2D time-of-ﬂight (TOF), with echo time (TE) of
5.9 ms and repetition time (TR) of 25 ms. A T2-weighted (T2w) 3D
TSE sequence with restore pulse, and imaging parameters that were
speciﬁcally optimized for the gel visualization (TE/TR=142/550 ms,
echo train length (ETL)=17, voxel dimensions 0.7×0.7×0.7 mm3,
FoV 186×223, acquisition time 12 min), were applied to image the
polymer gel. A T1-weighted 2D TSE black-blood sequence (TE/TR=
8.6/800 ms, inversion time (TI)=500 ms, echo train length (ETL)=9,
voxel dimensions 0.6×0.6×2.0 mm3, Field of View (FOV) 180×192,
acquisition time 10 min) and a 3D TSE black-blood sequence (TE/TR=








Study protocol for treated and control groups.
Time point Day 0 Week 1 Week 2
Treated Blood collection Patency check Patency check
Graft surgery Drug–polymer injection Drug–polymer injec
Drug-polymer application
Control Blood collection Patency check Patency check
Graft surgery
Please cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101192×156, acquisition time of 12 min) were applied to visualize the
graft and blood vessel lumens [8].
2.5. Calculation of signal-to-noise ratio (SNR) and contrast-to-noise
ratios (CNR) of polymer signal
An MR image slice containing polymer signal was chosen from all
image slices available in the T2w polymer-optimized imaging series
available for that injection. Using MatLab software (Mathworks, Inc.,
Natick, MA), a region of interest was encircled within the polymer
signal and average pixel signal intensity was evaluated. SNR for
each in vivo polymer image was determined by dividing the average
polymer pixel intensity by the noise (see Online Supplement) obtained
in the same image slice. SNR for background tissue near the polymer
was determined similarly. CNR for each polymer imagewas determined
by subtracting the SNR of the background from the SNR of the polymer.
The SNR and CNR values for each DICOM image were averaged to yield
an average and standard deviation SNR and CNR.
2.6. MR image analysis of venous anastomosis and juxta-anastomotic
tissues
OsiriX medical image processing software (Osirix v. 3.2.1), an
open-source software (http://www.osirix-viewer.com/Downloads.
html), was used for MR image analysis by three individual investiga-
tors (CT, HL, IZ) who were blinded to animal treatment at the time of
analysis. The narrowest cross-sectional lumen area at the anastomosis
of the vein and graft was measured by each investigator (see Fig. I in
Online Supplement) and the video ﬁle (See Video 1 in Online Supple-
ment). The measured lumen cross-sectional area was then normalized
by dividing by the total graft cross-sectional area (including the graft
wall and lumen) and multiplying by 100 and expressed as a percent
of graft area. All MRI data, with the exception of the 2D analysis of one
control animal, was deemed acceptable and was included in the
analysis.
2.7. Number of animals
At the beginning of this series of experiments, bilateral AV grafts
were placed in each animal. However, upon approval by the animal
care and use committee, the experimental protocol was subsequently
converted to unilateral grafts in order to decrease the surgical and
post-operative stress on the animals. In the ﬁnal analysis, there were
eleven animals in the sirolimus-treated group (see Table 2) with ﬁve
animals receiving bilateral grafts and six receiving unilateral grafts.
There were twelve animals in the control group with nine animals
receiving bilateral grafts and three receiving unilateral grafts. When a
single graft was placed in an animal, the side receiving the graft was
chosen at random. A total of 51 grafts were placed in 32 animals. How-
ever, animals in which the grafts were occluded within three weeks of
surgery (ﬁve animals) or animals that were euthanized for any cause
prior to the pre-determined six-week endpoint (four animals)were ex-
cluded from analysis. The decision to exclude such animals was made
prior to examination of the raw data. The rationale for excluding theWeek 3 Week 4 Week 5 Week 6
Patency check Patency check Patency check MRI
tion Drug–polymer injection Blood collection
Euthanasia
Patency check Patency check Patency check MRI
Blood collection
Euthanasia
ivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
Fig. 2. Ultrasound (US)-guided injection of sirolimus-laden polymer gel. (A) A Chiba-
type needle was inserted at the graft–vein anastomosis perivascular region under ster-
ile conditions while imaging with an US probe. (B) A drawing showing the position of
the Chiba-type needle in relation to the graft–vein anastomosis after US-guided place-
ment. Arrow in vein depicts blood ﬂow. (C) A US image of the needle and graft–vein
anastomosis just prior to polymer gel injection. (D) A US image of the graft–vein anas-
tomosis obtained during polymer injection.
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to apparent technical problems as no signiﬁcant hyperplasia could be
demonstrated at these early time points. Only animals that were main-
tained to the six-week endpoint were included in the ﬁnal analysis.
2.8. Explantation of venous anastomosis and juxta-anastomotic tissues
With the animal under general anesthesia, the AV graft and at-
tached native vessels were ligated. The lumens of the ligated vessels
were rinsed with saline, and perfused with 10% zinc-formalin to ﬁxPlease cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101the anatomical structures and maintain the lumen circumference.
After euthanasia, the grafts and ligated vessels were explanted en
bloc and ﬁxed in formalin overnight, parafﬁn embedded and sub-
jected to morphometric analysis as illustrated in Fig. 3 and described
in the Online Supplement [6].
2.9. Statistical analysis
The software package SAS (v9.2) was used for statistical analysis.
Mean±SD values were calculated for continuous variables. A one-
sided Wilcoxon two-sample test was used to test differences i) be-
tween the H/G ratios (ratios between the cross-sectional area of the
neointimal hyperplasia and the cross-sectional area of the AV graft)
calculated from graft histology sections (heel, middle and toe sec-
tions) obtained from treated and control animals, and ii) between the
lumen cross-sectional areas at the graft–vein anastomosis of treated
and control animals as determined in MR images. To test the difference
in occlusion rates of grafts between treated and control, a chi-square
contingency table analysis was done. ANOVA was used to test differ-
ences in blood chemistries between pre-operative values and values
at six post-operative weeks for control or treated animals.
3. Results
3.1. Study protocol and summary of morbidity and mortality
A summary of the study protocol is provided in Table 1. As indicated
in Table 2, a total of 23 animals with 32 grafts were used in the ﬁnal
analyses of hyperplasia. Also presented in Table 2 is a summary of the
morbidity, mortality as well as early and late graft occlusions. There
was no signiﬁcant difference in early occlusion rates between the treated
and control groups (23.1% vs. 26.1% respectively; p=0.81). There was a
trend toward fewer late (after the 3rd week) occlusion events in the
treated grafts compared to controls but this did not reach signiﬁcance
(3.6% vs. 21.7%; p=0.178).
Five of the 18 treated animals experienced some localized swelling
and exudate near the graft. In two of these ﬁve animals, the swelling
was observed at ﬁve and six weeks after surgery respectively but was
well tolerated and not associated with anorexia or weight loss. These
two animals were maintained to the six-week close-out time point
and included in the ﬁnal analyses for hyperplasia. Three of the ﬁve
animals experienced marked swelling within two weeks of graft
placement that affected the animals’well-being. These three animals
were euthanized before the planned six-week time point and were
excluded from the ﬁnal analyses for hyperplasia. Gram stain of the
exudates showed very few leukocytes and no bacteria (data not
shown). No bacteria were cultured from the exudate tested. In con-
trast, no remarkable local swellings were observed in any control an-
imals. In a separate series of study, the polymer gel alone without
sirolimus was applied to the venous anastomosis in ﬁve animals,
with no apparent untoward local or systemic effects observed up to
four weeks (data not shown).
3.2. MR imaging of polymer gel depot in vivo
MR with pulse sequences optimized to capture the polymer gel
was used to monitor the localization of the US-guided injection of
the gel. The mean contrast-to-noise ratio (CNR) of the polymer from
MR images of 17 injections was 82.6±44.8, indicating that our opti-
mized pulse sequence yielded excellent visualization of the polymer
gel. Fig. 4 shows the typical results of an MR scan obtained directly
after injection. Fig. 4B shows an MR image obtained immediately
after gel injection using the polymer-optimized scan parameters
and shown in the transverse (axial) plane. The image shows that, in
this animal, the gel was injected perivascular to the external jugularivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
Table 2















Treated 18 (28) (6)g 3 3 (5) 1 (2) 11 (15) 1 (1)
Control 14 (23) (6)g 2 0 0 12 (17) 4 (5)
a There are more grafts than pigs because some animals received bilateral grafts.
b These grafts were not included in the ﬁnal hyperplasia analysis because occlusion occurred within three weeks of surgery, when signiﬁcant hyperplasia was absent. Nine control
animals had bilateral grafts, and 4 of those animals had 1 graft experiencing early occlusion (4 of the 6); ﬁve treated animals had bilateral grafts, and 1 of those animals had 1 graft
experiencing early occlusion (1 of the 6). Other occlusions occurred in unilateral grafts.
c These animals had occlusion within three weeks of surgery in either their only graft or in both grafts, thus these animals were not included in the ﬁnal analysis. The grafts from these
animals are included in the “graft with early occlusion” column to the left.
d Three animals experienced marked exudate and swelling after polymer/drug application and were euthanized before the six-week time point.
e One treated animal was lost before the six-week time point due to accidental injection of polymer into the vein at 3 weeks after surgery.
f Late occlusion was deﬁned as occlusion that occurred after three weeks of graft placement. These animals were included in the ﬁnal analysis.
g These grafts were not included in the ﬁnal hyperplasia analysis.
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whereupon the polymer signal was still visible but appeared to have
diffused slightly toward the skin surface and underneath the vein
(Fig. 4C). Further, the signal intensity decreased, suggesting that the
gel had undergone compositional changes, such as a decrease in mass
due to diffusion of low molecular weight components of the polymer,
during this time interval. We measured the changes in CNR of polymer
depots over time in seven animals. In ﬁve of these animals, the CNR
decreased by between 55% to 80% three or four weeks after the initial
injection (see Fig. II in the Online Supplement). By comparison, when
the polymer gel was incubated in 2% bovine serum albumin in saline
at 37 °C with sink conditions, almost complete polymer breakdown
was observed by six weeks.
The majority of swelling and exudate that occurs with the initial
surgery typically subsided within ﬁve days after graft placement but
occasionally polymer was injected before the swelling had completely
subsided. In such an instance the gel-optimized pulse sequence showed
the presence of a bright signal where no polymer had been injected.
When the area was examined on images collected using a black-blood
pulse sequence, the bright signal was markedly diminished but the
polymer signal still retained a higher CNR (Fig. III in the Online Sup-
plement). In vitro studies of polymer and serum showed similar T1
and T2 relaxation times (Table I Online Supplement). This suggestedFig. 3. Tissue sampling at the AV graft for morphometric analysis. In the “middle” histology se
surface area “H” is outlined by a thin solid black line; the mouth of the graft is delineated by a d
reinforcement is shown surrounding the graft in the cartoon.
Please cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101that the bright signal observed in absence of polymer injection was
likely due to the presence of serum exudate still present from the sur-
gical wound. In further support, when such an animal was imaged
at later time points, the bright signal, purportedly from serum/exudate,
had largely resolved but signal from polymer, was still apparent (Fig. IV
Online Supplement). This data indicates that polymer gel can be differ-
entiated from serum exudate by MRI.3.3. Validation of MR image of injected polymer gel by gross visual
examination
To further conﬁrm the veracity of MR imaging of the polymer,
we compared MR image with direct visual inspection. To that end, a
highly lipophilic and hydrophobic dye (Sudan Black) was mixed with
the liquid polymer and injected at the perivascular anastomotic region
nine days after graft placement without US guidance. Fig. 5 shows
MR images obtained before (Fig. 5A) and after (Fig. 5B). Fourteen days
later, the injection site was exposed surgically for gross inspection.
The location and shape of the dye visualized grossly (Fig. 5C) were
very similar to those indicated by the MRI. These data further validated
the accuracy of MRI with optimized pulse sequences for monitoring the
polymer gel in vivo.ction, the ePTFE graft surface area “G” is outlined by a white dashed line; the hyperplasia
ashed black line to demonstrate the H/G ratio technique. “L” is the vein lumen. The spiral
ivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
Fig. 4. MRI of the polymer location and degradation. (A) An axial 2D TOF image of the
porcine neck. Grafts are indicated by the open-head arrows. Polymer was injected at
the region indicated by the bracket. (B) An MRI of the neck of the same animal shown
in panel A, obtained immediately after injection using a T2-w polymer-optimized
sequence showing the polymer in the transverse (axial) plane near the jugular vein
(labeled as “vein”). (C) MRI obtained from the same animal one week later.
Fig. 5. Validation of the polymer MR image by gross visual inspection. (A) A transverse
plane of an MR image obtained immediately before and (B) after injection of the poly-
mer (indicated by the dotted arrow) into a muscle near the graft. (C) Surgical exposure
of the area 14 days after injection revealed the dye (dotted arrow) to be in the same
location.
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Hyperplasia at the anastomosis of the vein and graft was quanti-
ﬁed on histological slides of cross-sections at the “toe”, the “middle”
and the “heel” regions of explanted tissues (refer to Fig. 3 in Materials
and methods). The results are shown in Fig. 6. Perivascular sustained
delivery of sirolimuswas associatedwith signiﬁcantly decreased hyper-
plasia in the middle sections of the graft, compared to the control
(0.43 mm2 hyperplasia per mm2 of graft area vs. 0.89 mm2 hyperplasia
per mm2 of graft area; pb0.003).
3.5. Perivascular sirolimus treatment increases AV graft lumen area
All 11 sirolimus-treated animals and eight of 12 control animals
underwent MRI. Lumen cross-sectional areas in both 2D- and 3D-
black-blood MR images were measured. (An example is shown in
Fig. I of the Online Supplement). The results are shown in Fig. 7 and,
as a normalization factor, are expressed as percentages of the graft
cross-sectional areas obtained in the same location. Perivascular sus-
tained delivery of rapamcyin was associated with a lumen cross-
sectional area that was signiﬁcantly increased, compared to control
animals. When expressed without normalization, the average lumenPlease cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101area of the treated grafts was 5.3 mm2 vs. an average lumen area of
2.5 mm2 for the control grafts pb0.05).
3.6. Other outcomes
At the end of the six-week study period, systemic plasma sirolimus
levels were below the assay detection limit of 2 ng/mL in six of the
ten animals that received perivascular sustained delivery of sirolimusivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
Fig. 6. Perivascular treatment with sirolimus is associated with decreased hyperplasia
formation at the venous anastomosis. Histological cross-sections from “toe”, “middle”
and “heel” regions at the venous anastomosis of sirolimus-treated grafts and control
grafts underwent morphometric analysis. The cross-sectional surface area of the hyper-
plasia (H) was normalized by the cross-sectional surface area of the graft (G) and
expressed as the H/G ratio. Each bar represents mean±SD.
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animals, the plasma sirolimus levels were slightly above the detection
limit and ranged from 2.75 ng/mL to 3.6 ng/mL (Table 3). Sirolimus
was undetectable in the plasma of all seven control animals that were
tested. No statistically signiﬁcant differences in blood chemistries
were observed between the treated and control animals at six weeks
after graft placement (Table 3).4. Discussion
Our previous study employing the same approach in the same
porcine AV graft model showed that repeat perivascular application
of sirolimus-loaded polymer gel resulted in clinically relevant levels
of drug in the venous anastomotic tissues [5]. The data presented in
the current study indicated that this approach was indeed effective
in the inhibition of stenosis in AV grafts. At the end of the six-week
period after graft placement, the average cross-sectional hyperplasia
surface area in the middle section of the venous anastomosis was
decreased by more than 50%, compared to the control grafts (Fig. 6).Fig. 7. Perivascular treatment with sirolimus is associated with increased cross-sectional
lumen area at the venous anastomosis. The venous anastomoses in sirolimus-treated
grafts and control grafts underwent both 2D and 3D black-blood MR imaging. Each bar
represents mean±SD.
Please cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101Morphometric analysis on histology slides is the most common
method for the quantiﬁcation of neointimal hyperplasia. It is, however,
labor-intensive and requires explantation of the vascular tissues, thus
prohibiting the serial monitoring of the hyperplasia over time. Histo-
logical analysis can also be complicated by artifacts, such as shrinkage
of the vascular tissues that often occurs immediately after explanation
andwith formalin ﬁxation. For the assessment of hyperplasia associated
with ePFTE grafts, there is an additional problem because the large dif-
ference in consistency of the ePTFE material and native vascular wall
makes sectioning the tissue block technically difﬁcult while maintaining
the integrity of the components. For these reasons, we established the
MRI method of imaging the AV graft in vivo [8]. With this technique,
the vascular lumen was imaged in vivo without the administration of
contrast, which would confer a distinct advantage in patients with
end-stage renal diseasewho are prone to develop nephrogenic systemic
ﬁbrosis with exposure to gadolinium [9]. The minimum lumen cross-
sectional area was assessed and quantiﬁed using DICOM imaging soft-
ware. Theminimum lumen cross-sectional area is a crucial determinant
of the blood ﬂow through the graft. Using MRI in the present study, the
minimum cross-sectional lumen area at the venous anastomosis in the
sirolimus-treated grafts was more than twice as large as that observed
in the control grafts at the end of the six-week period. A further advan-
tage of the MRI technique over histology is that it allows for the evalua-
tion of the lumen geometry along the entire length of the vessel of
interest.
Monitoring the localization of the administered polymer gel in vivo
is essential for the development of this treatment strategy. Using MRI
techniques, wewere able to conﬁrm that the polymer gels were admin-
istered to the target anastomotic region and remained at that location
during the course of follow-up (Fig. 4). MRI was also useful in monitor-
ing the disintegration of the administered polymer gel in vivo. In the
present study, the MRI signal of the polymer gel decreased by up to
80% at three to four weeks after injection. In contrast, complete break-
down of polymer was observed in vitro by six weeks. This apparent
faster degradation of the polymer gel in vivo than in vitro in the present
study was compatible with the previous kinetic studies reported by
Zentner et al. where a subcutaneous depot of the gel degraded by six
weeks in contrast to approximately eight weeks in vitro [7]. Using gel
permeation chromatography, they reported that the degradation of
the gel in vivo followed the pattern, albeit accelerated, of that observed
in vitro at 37 °C. The breakdown of the gel occurs by hydrolysis to lactic
acid, glycolic acid and PEG1000. The presence of catabolic enzymes, and
inﬂammatory cells as well as possible accumulation of acidity is a po-
tential contributing factor to enhanced degradation in vivo. Degradation
in a deep surgical wound site could also occur more quickly than at a
site of simple subcutaneous injection as the surgical wound typically
has more ﬂuid and inﬂammatory cells. Recently, Kempe et al. reported
the use of benchtop MRI for in vivo imaging of the degradation and en-
capsulation of subcutaneous PEG400/PLGA implants in mice over a
period of seven weeks [10]. Madhu et al. monitored the degradation
of a variety of subcutaneously injected depot formulations in vivo in
rats using MRI and found that the signals of the Poloxamers 407 and
188 disappeared by 45 h [11]. To our knowledge, the present study
was the ﬁrst to report the tracking by MRI of a drug delivery polymer
applied to a deep anatomical site or a perivascular region, and in a
large animal in particular. A further advantage of this MR imaging
technique is the higher resolution image of the polymer gel, com-
pared to that provided by even contrast-enhanced 3D multi-planar
computerized tomography (CT) [12].
Using a similar porcine model of AV graft stenosis, Rotmans et al.
reported a signiﬁcant reduction in hyperplasia development at the
venous anastomosis after placement of sirolimus-eluting stents, com-
pared to bare-metal stents or unstented controls [13]. However, stent
placement required cannulation of the synthetic graft, and a high in-
cidence of thrombosis occurred that necessitated the addition of the
antiplatelet agent abciximab, in addition to aspirin and clopidogrel,ivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
6/j.jconrel.2012.03.011
Table 3
Plasma sirolimus levels and serum chemistry at baseline (pre-operative) and six weeks after grafts-placement surgery in control and treated groups.








AST (IU/L) ALT (IU/L) WBC (103/mL)
Baseline
Control (12) b.d. (7); NA (5) 130±26 8±3 0.9±0.1a 25±4 41±9b 13.6±2.8
Treated (11) b.d. (11) 133±26 9±3 1.0±0.1c 26±7 51±12 15.5±2.8
Six weeks
Control (12) b.d. (7); NA (4) 167±64 9±2 1.3±0.2 34±13 53±9 11.6±2.8
Treated (11) 2.3 ng/mL; 3.6 ng/mL; 2.2 ng/mL; 2.9 ng/mL; b.d.a (6); NA (1) 154±44 8±2 1.3±0.3 27±6 57±7 12.6±2.8
b.d.—below detection limit of 2 ng/mL.
NA—not available due to inability to collect sufﬁcient volume of blood.
a pb0.02, baseline vs. six-week creatinine in control group.
b pb0.04, baseline vs. six-week ALT in control group.
c pb0.02, baseline vs. six week creatinine in treated group.
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delivery approach did not involve cannulation of the synthetic graft
and no increased risk of early occlusion occurred in our study. Drug-
eluting stents were designed to inhibit restenosis that is initiated by a
single insult to the vessel wall, such as balloon angioplasty. In contrast,
the bypass or interposition graft to the peripheral artery and the AV
graft are subjected to chronic pro-proliferative stimuli as a result of
highly aberrant vascular wall mechanical stress forces. The AV graft is
also unique in that it suffers frequent needle trauma from cannulation
for hemodialysis access. Additionally, the uremic milieu that is present
in the hemodialysis population renders their vascular wall abnormal
on a chronic basis; for example, nitric oxide production is subnornal.
This myriad of chronic stimuli necessitates chronic suppressive therapy
for neointimal hyperplasia. In the clinically used coronary drug-eluting
stents, sirolimus is depleted within 90 days with the majority of the
drug being released in the ﬁrst 30 days [14]. Thus, drug-eluting stents
may not be sufﬁcient for long-term stenosis prevention in the AV
graft. Our current approach is particularly attractive in the hemodialysis
AV access setting since its superﬁcial location (almost exclusively in the
arm) allows for repeat percutaneous injection of the sustained delivery
polymer to the venous anastomosis.
The sirolimus concentrations in the vessel wall were determined
in a previous pharmacokinetic study [5] and have now been refor-
matted and presented in Table 4. Based on that earlier study, only ap-
proximately 6% of the total administered dose was accounted for in
the vascular tissue at the two-week time point, which was substan-
tially lower than the 65% release expected from the previous in
vitro pharmacokinetic experiments. The tissue concentrations at six
weeks were considerably lower than the concentrations at two weeks.
An intact polymer depot could not be retrieved at the later time points;
thus the amount of drug remaining in the depot could not be deter-
mined to calculatemore deﬁnitivemass balance. The inability to account
for all drug in the in vivo system is likely due to loss from metabolism,Table 4
Venous anastomotic tissue concentrations of sirolimus after graft placement in the treated
Time of explants Number of drug applications
One week One (applied at time of surgery)
Two weeks Two (applied at time of surgery; injected one week
after surgery)
Six weeks Four (applied at time of surgery; injected one, two and
three weeks after surgery)
Tissue concentrations of drug were previously reported in a different from but are included
a Maximum concentration indicates the highest amount of drug that was found within a r
of the contiguous vein at the time point indicated.
b Tissue used for this analysis included the venous anastomosis and ~3 cm of contiguous
c Molarity was calculated based on the mol. weight of 914.2 g/mol and assuming that 1 c
Please cite this article as: C.M. Terry, et al., In vivo evaluation of the del
hyperplasia in a porcine model ..., J. Control. Release (2012), doi:10.101diffusion to surrounding nonvascular tissue, and/or wash out in the
luminal blood stream. A tissue concentration of 248 ng/g observed in
the vascular wall at six weeks is approximately equal to 271.3 nmol/L,
given the molecular weight of sirolimus of 914.2 and assuming the
density of the vein tissue to be 1.0 g/mL. The IC50 of sirolimus for the
inhibition of porcine venous smooth muscle cells in vitro is 3.4 ng/mL
(3.7 nmol/L) [15]. Therefore, the tissue drug concentration achieved
in vivo in our animal model was two to three orders of magnitude
greater than the necessary concentrations required for the inhibition
of cultured porcine smooth muscle cell proliferation. The ideal siroli-
mus amount in the polymer and application time points to achieve
maximum stenosis inhibition and safety are yet to be determined. If
necessary, the drug release kinetics from the polymer can be modiﬁed
to achieve desired proﬁles by altering the molecular weight and ratio
of the speciﬁc polymer components [7]. It is possible that fewer drug
applications or applications spaced further apart in time would have
been efﬁcacious as well.
The systemic exposure to sirolimus in the present study, as indi-
cated by the peripheral plasma drug concentrations, appeared to be
minimal. However, there was substantial swelling with exudate at the
site of drug application in three of 18 treated animals (an incidence of
16.7%) that required early termination from the study. In two of these
three animals, the formulation used in the ﬁrst, but not subsequent,
applications included dimethylsulfoxide (DMSO), which was subse-
quently discontinued in our animal experiments. The swelling had not
been observed in other animals in previous experiments when the
identical triblock polymer alone was administered to the perivascular
area. Thus, the swelling could potentially be a result of exposure of
the tissues to high concentrations of sirolimus. The addition of DMSO
did not appear to signiﬁcantly alter the in vitro release rate of sirolimus.
Local toxicity of sirolimus appears to be dose-dependent. Recently,
Rajathurai et al. reported that approximately 25% of porcine vein-to-
artery interposition grafts ruptured, typically within 5–7 days aftergroup.
Total amount of
drug applied
Max.a tissue contraction of drug: ng drug/g
tissue (molar concentration)b
5 mg 2.4±0.6 ng/g
(2.6 nmol/L)c
10 mg 1561±37 ng/mg
(1707.5 nmol/L)c
20 mg 248±13 ng/mg
(271.3 nmol/L)c
here for completeness.
egion of vein tissue 3 cm distal or proximal to the venous anastomosis along the length
proximal and distal vein segments.
m3 of tissue weighed 1 g.
ivery and efﬁcacy of a sirolimus-laden polymer gel for inhibition of
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of graft using polyvinyl alcohol microspheres suspended in pluronic
gel as the delivery platform [16]. They estimated that 60% of the drug
was released by four days, whereas the release of sirolimus from the
triblock polymer gel in our in vitro study was only approximately 20%
in four days [5]. Kawatsu et al. reported inhibition of hyperplasia in a
canine model of femoral artery interposition grafts after wrapping
with a biodegradable copolymer ﬁlm embedded with up to 800 mg of
sirolimus but reported no toxicity [17]. Additionally, Schachner et al.
did not report any toxicity when a pluronic gel laden with 200 mg
sirolimus was delivered perivascularly to inferior vena cava grafts
in a mouse model [18].
In conclusion, perivascular delivery of sirolimus is an attractive
means to inhibit neointimal hyperplasia development. The sustained
delivery of this drug over a prolonged duration by repeat percutaneous
injection of the drug-laden polymer is particularly useful under condi-
tions of chronic stimulus, such as the AV graft used for hemodialysis.
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